Is it worth buying Humana stock at a price of $399.78? If this question is on your mind, make sure to check out the fundamentals of this Medical Specialities large-cap company:
-
Humana has logged a -18.8% 52 week change, compared to 20.4% for the S&P 500
-
HUM has an average analyst rating of buy and is -28.39% away from its mean target price of $558.28 per share
-
Its trailing earnings per share (EPS) is $24.17, which brings its trailing Price to Earnings (P/E) ratio to 16.5. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $30.17 and its forward P/E ratio is 13.3
-
The company has a Price to Book (P/B) ratio of 2.9 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 1.4, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
HUM has reported YOY quarterly earnings growth of -28.5% and gross profit margins of 0.2%
-
The company's free cash flow for the last fiscal year was $5.01 Billion and the average free cash flow growth rate is 10.4%
-
Humana's revenues have an average growth rate of 10.9% with operating expenses growing at 11.6%. The company's current operating margins stand at 4.4%